JURNISTA TABLET (EXTENDED-RELEASE)

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

HYDROMORPHONE HYDROCHLORIDE

Prieinama:

JANSSEN INC

ATC kodas:

N02AA03

INN (Tarptautinis Pavadinimas):

HYDROMORPHONE

Dozė:

16MG

Vaisto forma:

TABLET (EXTENDED-RELEASE)

Sudėtis:

HYDROMORPHONE HYDROCHLORIDE 16MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30

Recepto tipas:

Narcotic (CDSA I)

Gydymo sritis:

OPIATE AGONISTS

Produkto santrauka:

Active ingredient group (AIG) number: 0108698014; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2018-10-31

Prekės savybės

_232334 APM.doc_
_ _
_Page 1 of 52 _
PRODUCT MONOGRAPH
N
JURNISTA
®
HYDROmorphone hydrochloride Prolonged Release Tablets
4, 8, 16, and 32 mg
Opioid Analgesic
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.janssen.com/canada
Distribution Site:
Markham, Ontario
L3R 0T5
Date of Preparation:
November 17, 2009
Date of Revision:
December 13, 2019
SUBMISSION CONTROL NO.: 232334
All trademarks used under license.
© 2019 Janssen Inc.
_232334 APM.doc_
_ _
_Page 2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
14
DRUG INTERACTIONS
.........................................................................................................
20
DOSAGE AND ADMINISTRATION
.....................................................................................
22
OVERDOSAGE
.......................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 28
STORAGE AND STABILITY
.................................................................................................
31
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 31
PART II: SCIENTIFIC INFORMATION
.....